Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ark Diagnostics Inc. maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are consolidated under 1 distinct examiner and 1 distinct art unit. This indicates a narrow prosecution footprint where 1 individual oversees the pending portfolio. Such concentration can lead to a consistent prosecution experience, as the company is dealing with 1 set of examiner preferences and 1 art unit's standards. Practitioners should note that the company's current active presence at the patent office is confined to this specific area of biotechnology.
The busiest examiner, HAQ, SHAFIQUL, is currently managing 2 pending office actions. Since the total number of pending actions is 2, this examiner is responsible for the 2 pending office actions. This centralization simplifies the coordination of responses but makes the outcome of the company's patent efforts dependent on 1 examiner's perspective. The lack of broader distribution across examiners or art units means that the outcome of these 2 cases will define the company's current patent status in this technology area. Building a clear record with HAQ, SHAFIQUL is the primary task for the company's current prosecution efforts. Practitioners must address the specific requirements of this 1 examiner to advance the 2 pending applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 2 | 64.8% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | — |
| 18523548 | Compounds and Methods for Use in Detecting Gabapentin | HAQ, SHAFIQUL | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | 1678 | §103§112 | Final Rejection | — | Pending | Feb 13, 2026 |
| 18523548 | Compounds and Methods for Use in Detecting Gabapentin | HAQ, SHAFIQUL | — | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial